In vitro and in vivo evaluations of the efficacy and safety of skin permeation enhancers using flurbiprofen as a model drug

International Journal of Pharmaceutics

Volumn 255, Issue 1-2, 2003, Pages 153-166

  Fang, Jia You ^a   Hwang, Tsong Long ^a   Fang, Chia Lang ^b   Chiu, Hsien Chih ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bioengineering method; Cell culture; Enhancer; Flurbiprofen; Irritation; Percutaneous absorption

Indexed keywords

FLURBIPROFEN; LAUROCAPRAM; LIMONENE; PHOSPHATIDYLCHOLINE; PROSTAGLANDIN E2; UNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL TYPE; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG SCREENING; ERYTHEMA; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MODEL; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RAT; SKIN IRRITATION; SKIN PERMEABILITY; SKIN WATER LOSS;

EID: 0037436962     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00086-3     Document Type: Article

References (28)

1. Adams J., Collaco-Moraes Y., de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J. Neurochem. 66:1996;6-13.
2. Agache D.G., Dupond A. Recent advances in non-invasive assessment of human skin blood flow. Acta. Derm. Venereol. Suppl. 185:1994;47-51.
3. Agner T., Serup J. Skin reactions to irritants assessed by non-invasive bioengineering methods. Contact Dermat. 20:1989;352-359.
4. Bason M.M., Gordon V., Maibach H.I. Skin irritation: in vitro assays. Int. J. Dermatol. 30:1991;623-626.
5. Boelsma E., Tanojo H., Bodde H.E., Ponec M. Assessment of the potential irritancy of oleic acid on human skin: evaluation in vitro and in vivo. Toxicol. In Vitro. 10:1996;729-742.
6. Chen H.Y., Fang J.Y. Therapeutic patents for topical and transdermal drug delivery systems. Exp. Opin. Ther. Patents. 10:2000;1035-1043.
7. Díez-Sales O., Watkinson A.C., Herráez-Domínguez M., Javaloyes C., Hadgraft J. A mechanistic investigation of the in vitro human skin permeation enhancing effect of Azone. Int. J. Pharm. 129:1996;33-40.
8. Fang J.Y., Leu Y.L., Wang Y.Y., Tsai Y.H. In vitro topical application and in vivo bioengineering evaluation of nonivamide hydrogels using Wistar rat as an animal model. Eur. J. Pharm. Sci. 15:2002;417-423.
9. Fang J.Y., Tasi M.J., Huang Y.B., Wu P.C., Tsai Y.H. Percutaneous absorption and skin erythema: quantification of capsaicin and its synthetic derivatives from gels incorporated with benzalkonium chloride by using non-invasive bioengineering methods. Drug Dev. Res. 40:1997;56-67.
10. Finnin B.C., Morgan T.M. Transdermal penetration enhancers: application, limitation, and potential. J. Pharm. Sci. 88:1999;955-958.
11. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:1994;55-59.
12. Heyneman C.A., Lawless-Liday C., Wall G.C. Oral versus topical NSAID in rheumatic diseases. Drugs. 60:2000;555-574.
13. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Lee C.A., Goulding E.H., Kluckman K.D. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:1995;483-492.
14. Phillips C.A., Michniak B.B. Topical application of Azone analogs to hairless mouse skin: a histopathological study. Int. J. Pharm. 125:1995;63-71.
15. Poul J., West J., Buchanan N., Grahame R. Local action transcutaneous flurbiprofen in the treatment of soft tissue rheumatism. Br. J. Pharmacol. 32:1993;1000-1003.
16. Queille-Roussel C., Poncet M., Schaefer H. Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta chromameter. Br. J. Dermatol. 124:1991;264-270.
17. Rijzewijk J.J., Bauer F.W., Boezeman J.B.M., Happle R., Mier P.D. Recruitment of quiescent cells following epidermal injury is initiated by activation of phosphoinositol cycle. J. Invest. Dermatol. 90:1988;44-47.
18. Schneider I., Dobner B., Neubere R., Wohlrab W. Evaluation of drug penetration into human skin ex vivo using branched fatty acids and propylene glycol. Int. J. Pharm. 145:1996;187-196.
19. Serup J., Agner T. Colorimetric quantification of erythema - a comparison of two colorimeters with a clinical scoring scheme and laser Doppler flowmetry. Clin. Exp. Dermatol. 15:1990;267-272.
20. Snater E., Janssen E.A.A.J., Van der Valk P.G.M., Van de Kerkhof P.C.M. Transepidermal water vapour loss is not increased during and following dithranol irritation. Br. J. Dermatol. 132:1995;908-912.
21. Stoughton R.B. Enhanced percutaneous penetration with 1-dodecylazocycloheptan-2-one. Arch. Dermatol. 118:1982;474-477.
22. Sugibayashi K., Nakayama S., Seki T., Hosoya K., Morimoto Y. Mechanism of skin penetration-enhancing effect by laurocapram. J. Pharm. Sci. 81:1992;58-64.
23. Takeuchi Y., Yasukawa H., Yamaoka Y., Taguchi K., Fukushima S., Shimouaka Y., Nishinaga H., Morimoto Y. Behavior of propylene glycol in dermis after treatment of rat intact skin surface with fatty acids, fatty amines or Azone dissolved in propylene glycol. Biol. Pharm. Bull. 18:1995;304-309.
24. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:1995;493-501.
25. Valjakka-Koskela R., Kirjavainen M., Mönkkönen J., Urtti A., Kiesvaara J. Enhancement of percutaneous absorption of naproxen by phospholipids. Int. J. Pharm. 175:1998;225-230.
26. Wahlberg J.E., Nilsson G. Skin irritancy from propylene glycol. Acta. Derm. Venereol. 64:1984;286-290.
27. Xu P., Chien Y.W. Enhanced skin permeability for transdermal drug delivery: physiopathological and physicochemical considerations. Crit. Rev. Ther. Drug Carrier Sys. 8:1991;211-236.
28. Zhao K., Singh J. Mechanisms of in vitro percutaneous absorption enhancement of tamoxifen by enhancers. J. Pharm. Sci. 89:2000;771-780.